Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva makes $40B offer for Mylan
Justice Dept reportedly may file charges in its generic-drug probe by year-end
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel
Teva Agrees to Purchase Rimsa in $2.3 Billion Deal
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
HSBC downgrades Teva on uncertainty surrounding DOJ's reported generic drug investigation
Teva Pharmaceuticals - Wikipedia
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Pharmaceutical: Value at Last - WSJ
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
